US4737462A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1985-07-10
•
Granted: 1988-04-12
•
Expires: 2005-07-10
Abstract
Abstract A modified IFN-β is provided wherein the cysteine residue at position 17 is deleted and serine is substituted therefor. DNA sequences coding for the modified protein, nucleotide primers used for the mutagenesis, appropriate cloning vectors, host organisms transformed with the vectors, methods for the production and use of the modified IFN-β (IFN-β ser17 ) are also provided. The specific activity of IFN-β ser17 is found to be substantially the same as that of native IFN-β.
Inventors
- 👤 David F. Mark
- 👤 Leo S. Lin
- 👤 Shi-Da Yu Lu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 15:58
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/55; C07K14/555; C07K14/565; C12; C12N; C12N15/00; C12N15/09; C12N15/10; C12N15/102; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/14; Y10S930/142
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
33 words
A structural gene having a DNA sequence that encodes a synthetic IFN-β wherein the cysteine residue at position 17, numbered in accordance with native human IFN-β, is replaced by a neutral amino acid.
Claim 2
Dependent Claim
33 words
A structural gene having a DNA sequence that encodes a synthetic IFN-β wherein the cysteine residue at position 17, numbered in accordance with native human IFN-β, is replaced by a neutral amino acid.
Claim 3
Dependent Claim
31 words
The structural gene of claim 1 wherein the neutral amino acid is selected from the group consisting of serine, threonine, glycine, alanine, valine, leucine, isoleucine, histidine, tyrosine, phenylalanine, tryptophan, and methionine.
Claim 4
Dependent Claim
15 words
The structural gene of claim 1, wherein the neutral amino acid is serine or threonine.
Claim 5
Dependent Claim
13 words
The structural gene of claim 1, wherein the neutral amino acid is serine.
Claim 6
Dependent Claim
17 words
The structural gene of claims 1, 2, 3, or 4 with or without an initial ATG codon.
Claim 7
Dependent Claim
15 words
The structural gene as represented in FIG. 10, with or without the initial ATG codon.
Claim 8
Dependent Claim
15 words
The structural gene as represented in FIG. 10, with or without the initial ATG codon.
Claim 9
Dependent Claim
15 words
An expression vector that includes that structural gene of claims 1, 2, 3 or 4.
Claim 10
Dependent Claim
8 words
The plasmid having an NRRL accession number B-15356.
Claim 11
Dependent Claim
8 words
The plasmid having an NRRL accession number B-15356.
Claim 12
Dependent Claim
70 words
A host cell transformed with an expression vector that includes a structural gene having a DNA sequence that encodes a synthetic IFN-β wherein the cysteine residue at position 17, numbered in accordance with native human IFN-β, is replaced by a neutral amino acid and said mutein exhibits the biological activity of native human IFN-β, wherein the host cell is selected from the group consisting of bacteria, yeast, animal, and plant.
Claim 13
Dependent Claim
70 words
A host cell transformed with an expression vector that includes a structural gene having a DNA sequence that encodes a synthetic IFN-β wherein the cysteine residue at position 17, numbered in accordance with native human IFN-β, is replaced by a neutral amino acid and said mutein exhibits the biological activity of native human IFN-β, wherein the host cell is selected from the group consisting of bacteria, yeast, animal, and plant.
Claim 14
Dependent Claim
12 words
The host cell of claim 9, wherein the host cell is bacteria.
Claim 15
Dependent Claim
12 words
The host cell of claim 10, wherein the bacteria is E. coli.
Claim 16
Dependent Claim
34 words
The host cell of claims 9, 10 or 11, wherein the neutral amino acid is selected from the group consisting of serine, threonine, glycine, alanine, valine, leucine, isoleucine, histidine, tyrosine, phenylalanine, tryptrophan, and methionine.
Claim 17
Dependent Claim
16 words
The host cell of claims 9, 10 or 11, wherein the neutral amino acid is serine.
Claim 18
Dependent Claim
23 words
E. coli transformed by an expression vector which includes the structural gene represented by FIG. 10, with or without the initial ATG codon.
Claim 19
Dependent Claim
23 words
E. coli transformed by an expression vector which includes the structural gene represented by FIG. 10, with or without the initial ATG codon.
Claim 20
Dependent Claim
10 words
E. coli transformed with the plasmid pSY2501 and progeny thereof.
Claim 21
Dependent Claim
10 words
E. coli transformed with the plasmid pSY2501 and progeny thereof.
References Cited (Backward Citations)
EP0028033A2
Cited
GB2063882A
Cited
EP0041313A2
Cited
EP0042246A2
Cited
US4414150A
Cited
EP0128467A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-04-12 | 1991-10-12 | 1992-04-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-04-12 | 1995-10-12 | 1996-04-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-04-12 | 1999-10-12 | 2000-04-12 | $7700.00 | Window Closed / Lapsed |